Back to Newsroom
Back to Newsroom

MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development

Friday, 23 February 2024 09:20 AM

Institute of BioMedical Research Corp.

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates:

M2Bio Sciences proudly announces the launch of its groundbreaking new division, M2BioKids, a pioneering initiative dedicated to enhancing mental and physical health in the formative years of life, from newborns to children aged five years. Rooted in the cutting-edge intersection of biotechnology and pediatric health science, M2BioKids is set to revolutionize early childhood development through a comprehensive approach encompassing food, nutrition, physical and mental exercises, and critical thinking via AI-driven apps.

The foundational years of a child's life are crucial for setting the stage for lifelong health, well-being, and cognitive abilities. Recognizing the immense potential for positive impact during this pivotal period, M2BioKids leverages the latest scientific research to develop innovative solutions and strategies to optimize growth, health, and developmental outcomes.

Nutritional Science: At the core of M2BioKids' mission is a deep commitment to advancing nutritional science for young children.

Understanding that proper nutrition is the cornerstone of healthy development, our research focuses on identifying optimal dietary patterns and micronutrient intakes that support brain development, immune system strength, and physical growth. Through the creation of scientifically formulated foods and supplements, M2BioKids aims to address common nutritional deficiencies and promote a foundation of health from the earliest stages of life.

Physical Development: Physical activity is another crucial pillar of M2BioKids' holistic approach. Recognizing the critical role of physical development in early childhood, our programs are designed to encourage age-appropriate motor skills through playful, engaging exercises that promote strength, coordination, and overall physical health. By integrating these activities into daily routines, M2BioKids supports the natural growth process while laying the groundwork for an active, healthy lifestyle.

Mental and Cognitive Enhancement: M2BioKids is equally focused on the mental and cognitive aspects of early childhood development. We aim to stimulate critical thinking, problem-solving, and creativity by developing innovative educational tools and programs. Our approach is rooted in the latest cognitive science, ensuring our methods engage young minds and support neural development, language acquisition, and emotional intelligence.

Research and Development: At the heart of M2BioKids is a robust research and development program committed to pushing the boundaries of what's possible in early childhood health and development. Our multidisciplinary team of scientists, pediatric health experts, and educators collaborate to explore new theories, conduct clinical trials, and translate discoveries into practical applications. This relentless pursuit of knowledge ensures that M2BioKids remains at the forefront of scientific advancement, delivering evidence-based solutions that make a real difference in the lives of children and their families.

Interactive AI-Driven App: M2BioKids is developing an interactive AI-driven app to enhance its impact further. This digital platform will engage children in learning activities while offering parents and caregivers valuable nutrition, physical activity, and cognitive development resources. The app will feature gamified learning experiences, interactive storytime, and movement challenges, making learning fun and educational. Personalized recommendations and developmental milestone tracking will provide a tailored experience that evolves with the child.

Market Need and Innovation: The launch of M2BioKids comes in response to a critical and underserved need in the early childhood development sector. Statistics underscore the global challenge of undernutrition, which is a contributing factor in nearly half of all deaths in children under five, highlighting the urgent need for improved nutritional science and interventions. Additionally, with over 130 million babies born each year worldwide, the demand for holistic, scientifically-backed developmental aids is increasing. M2BioKids addresses these needs by offering innovative solutions that promise to significantly impact the health and development of young children, presenting a compelling and sustainable business segment with extensive growth potential.

Future Directions: As M2BioKids grows and evolves, our vision extends beyond the immediate horizon. We are committed to expanding our research to cover a broader spectrum of childhood development issues, exploring innovative therapies, and developing new technologies that address the complex needs of growing children. With a foundation built on science, compassion, and innovation, M2BioKids is poised to lead a new era in childhood development, impacting future generations.

Jeff Robinson, CEO of M2Bio Sciences, stated: "M2BioKids is a groundbreaking initiative that epitomizes M2Bio Sciences' dedication to harnessing the power of AI, biotechnological innovations, and scientific research to enhance children's mental and physical health. By strategically focusing on the critical developmental windows from preconception through the early years, M2BioKids integrates advanced nutritional science, neurodevelopmental strategies, and pioneering digital tools to establish a robust foundation for lifelong health, cognitive well-being, and intellectual prowess. This approach not only aims to cultivate a generation that is healthier, more intellectually capable, and more adaptable to challenges but also sets a new benchmark in pediatric health science, promising a brighter, more resilient future for children globally."

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences

Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.

The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."

Publicly traded Company (OTC Pink:MRES)

[email protected]
+27 72 333 2148

Find M2Bio™ on social media


Forward-Looking Statements

Safe Harbour Statement - Besides historical information, this press release may contain forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team concerning the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments concerning litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Institute of BioMedical Research Corp.

Company Update
Back to newsroom
Back to Newsroom
Share by: